Kamada (KMDA)
Develops plasma-derived therapies and distributes biopharmaceutical products in Israel and the MENA region.
Something off on this page? Send us feedback.
Develops and manufactures specialty plasma-derived therapies, then commercializes its own and acquired products. Plasma sales, in-licensing partnerships and third-party biopharmaceutical distribution in Israel and the MENA region also support the business.
Develops, manufactures and commercializes specialty plasma-derived therapies for rare and serious conditions. Its marketed portfolio includes FDA-approved products and a development pipeline, while plasma sales and third-party biopharmaceutical distribution support operations in Israel and the MENA region. This vertically integrated model links product development, manufacturing and commercial distribution.
An acquisition expanded U.S. commercialization to direct sales through wholesalers and local distributors. The operating model combines manufacturing with product commercialization, in-licensing partnerships and regional distribution; its products are marketed in more than 30 territories. Nasdaq ordinary shares trade alongside a TASE listing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 18, 2026 | UBS | Reiterate | Rating: —Target: — | Target: $15 |
| Jul 21, 2026 | William Blair | Target | Target: — | Target: $15 |
| Mar 11, 2026 | Stifel Nicolaus | Target | Target: $20 | Target: $11 |
| Dec 9, 2025 | H.C. Wainwright | Target | Target: — | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $70.1M · Total debt $11.8M · Total assets $383.2M · Shareholders' equity $269.6M
- Revenue
- $54.9M
- Operating income
- $9.5M
- Net income
- $9.3M
HistoryDividendAnnual yield
| Institutions | 8.61% | 4.97M ADS | |
|---|---|---|---|
| 51 holders · as of Jun 30, 2026 | |||
| Insiders | 52.73% | 30.42M ADS | |
| 13 holders · as of Sep 17, 2026 | |||
| Other | 38.66% | 22.30M ADS | |
| remainder | |||
57.69M ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ishay DavidiInsiderdirector, 10 percent owner | 38.28% | 22.08M ordinary | filed Mar 23, 2026 |
Leon RecanatiInsider | 6.30% | 3.63M | filed Feb 13, 2020 |
Leon Recanati1Insiderdirector | 3.62% | 2.09M ordinary | filed Mar 16, 2026 |
Amir EfratiInsider | 3.61% | 2.08M | filed Jan 29, 2020 |
Phoenix Holdings Ltd.Institution | 2.87% | 1.65M ADS | as of Jun 30, 2026 |
- Reported at 2.50% on Mar 16, 2026, under the 5% line, so no further filing is required.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | David Tsur | director | −22,827 | $8.18 |
| Sep 9, 2026 | David Tsur | director | −175 | $8.26 |
| Sep 8, 2026 | David Tsur | director | −162,760 | $8.26 |
| Sep 7, 2026 | David Tsur | director | −14,238 | $8.28 |
- Grifols (ADR)
Direct rival in AAT augmentation and rabies immune globulin
- Takeda (ADR)
AAT augmentation rival through ARALAST NP
- ADMA Biologics
Plasma-derived biologics rival for capabilities and partnerships
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kamada | $8.75 | −1.41% | $511.7M | 23.4 | 17.3 | 2.7 | +22.7% |
| Grifols (ADR) | $7.29 | −1.99% | $6.29B | 9.7 | — | 0.7 | −1.8% |
| Takeda (ADR) | $18.82 | −0.69% | $60.30B | 52.9 | 59.8 | 2.0 | +4.2% |
| ADMA Biologics | $9.53 | −2.86% | $2.27B | 14.0 | 11.9 | 4.4 | +2.0% |
| Median | 14.0 | 35.9 | 2.0 | +2.0% |